Skip to content
ESPT
MARKETS / NYSE / Health care / Pharmaceuticals / EBS
NYSE · PHARMACEUTICAL PREPARATIONS · MID CAP

Emergent BioSolutions Inc. EBS

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$742.9M
▼ 28.8% YoY
$52.6M
$156.8M
▲ 338.0% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Emergent BioSolutions provides a product portfolio, a product development portfolio, and contract development and manufacturing services addressing accidental, deliberate and naturally occurring public health threats. As of December 31, 2025, it had a portfolio of 11 products focused on addressing global public health threats such as smallpox, mpox, anthrax, Ebola and opioid overdose emergencies. As of December 31, 2025, it had approximately 900 employees globally. The company has four development and manufacturing sites in the U.S. and Canada, with its Winnipeg and Gaithersburg sites housing development services, its Canton, Lansing and Winnipeg sites housing commercial drug substance production, and its Winnipeg site housing drug product and packaging operations. Emergent BioSolutions is organized into three operating segments: a Commercial Product Segment consisting of NARCAN Nasal Spray and KLOXXADO Spray, an MCM Products Segment consisting of Anthrax and Smallpox medical countermeasure products and other products, and a Services Segment consisting of its Bioservices portfolio. Its Government-MCM business focuses primarily on the procurement of MCM products and procured product candidates by domestic and international government customers, with an emphasis on the USG, which is its largest customer.

Written from the business description in Emergent BioSolutions Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.

Growth

USD 742.9M
Revenue, FY2025 · full 17-year series below
Revenue $B Net income $B
FY2025 · Revenue 0.7 · Net income 0.1
1.0B2.0B-0.3B-0.6B
2009201220152018202120242025
Compound annual growth
−12.7%
−14.0%
+4.3%
+6.6%
−29.7%
−1.8%
+0.1%
−30.4%
−4.1%
−3.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −14.0% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

7 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 13.5% · Net 7.1%
10%20%-20%-40%-60%
200920172025
ROE
FY2025 · ROE 10.5%
10%20%-20%-40%-60%
200920172025
Three returns, three denominators.
Gross margin56.1%
Operating margin13.5%
Net margin7.1%
EBITDAUSD 195.9M

Each USD of equity produced 10 cents of profit this year.

Cash & shareholders

USD 24.9M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 156.8
150M300M-100M-200M
200920172025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 24.9
50M100M-10M-20M
201020122014201620182020202220242025
Dividends paid·
Net buybacksUSD 24.9M
Share of profit47.3%
Consecutive raises·

USD 24.9M in buybacks — 47% of the year's profit went back to shareholders.

Total assetsUSD 1.3B
EquityUSD 522.6M
CashUSD 205.4M
Gross debtUSD 572.1M
Net debtUSD 366.7M
Current ratio5.01×

Net debt stands at 70% of equity.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
EBS, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.71.01.01.11.81.61.10.80.60.50.50.40.30.30.30.30.2
Operating income $B0.1−0.1−0.7−0.20.30.40.10.10.10.10.10.10.00.00.00.10.0
EBITDA $B0.20.0−0.6−0.00.50.50.20.10.20.10.20.10.10.00.00.10.0
Income tax $B0.00.00.0−0.00.10.10.00.00.00.00.00.00.00.00.00.00.0
Net income $B0.1−0.2−0.8−0.20.20.30.10.10.10.10.10.00.00.00.00.10.0
Free cash flow $B0.20.0−0.3−0.10.10.40.1−0.00.2−0.0−0.00.10.1−0.0−0.00.1−0.0
EPS, diluted $0.93−3.60−14.85−4.224.065.681.041.221.711.131.410.880.850.650.641.590.99
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————————
ROE %10.5−33.7−74.7−14.114.324.15.26.511.08.210.47.06.75.55.916.912.8
Shares out B0.050.050.050.050.050.050.050.050.050.040.040.040.040.040.040.04◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures · 4 divergences in 70 reconciliationsAUDITED

Reconciled in 13 of the 17 fiscal years we could check. 4 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009. Two checks were skipped: revenue is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures4 divergent
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image